Tocilizumab [roactemra] (DrugBank: Tocilizumab)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
46 | 悪性関節リウマチ | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01254331 (ClinicalTrials.gov) | February 2011 | 3/12/2010 | An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment | Open Label, Multicenter, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Monotherapy or in Combination With MTX in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non Biologic DMARDs | Rheumatoid Arthritis | Drug: tocilizumab [RoActemra] | Hoffmann-La Roche | NULL | Completed | 18 Years | N/A | All | 51 | Phase 3 | Tunisia |